Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma

NCT02947867 is registered in ClinicalTrials.gov with Gene Signal SAS as lead sponsor.

NCT NCT02947867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02947867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma
Lead sponsor
Gene Signal SAS
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 31, 2017
Completion date
December 31, 2019
Enrollment
333 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ischaemic central retinal vein occlusion, neovascular glaucoma